Mohit Bhutani, MD, FRCPC, University of Alberta, Edmonton, AB
Jean Bourbeau, MD, FRCPC, McGill University, Montreal, QC
Paul Hernandez, MDCM, FRCPC, Nova Scotia Health, Halifax, NS
Darcy Marciniuk, MD, FRCPC, FCAHS, Master FCCP, University of Saskatchewan, Saskatoon, SK 

This presentation will be on the new 2023 CTS guideline on the pharmacotherapy management of stable COPD with evidence-based recommendations from a systematic review and meta-analysis. The key clinical questions of the guideline were developed using the PICO model for 3 questions that focus on the outcomes of symptoms (dyspnea)/health status, acute exacerbations of COPD (AECOPD) and mortality.

The innovation of this guideline, and the first to our knowledge, is to systematically assess and report on the impact of maintenance pharmacotherapies on the important outcome of mortality in COPD. The presentation will also include the review of a practical treatment pathway based on new evidence and recommendations. Finally, a panel of experts will answer questions from the audience and engage in discussion.

Learning objectives:
At the end of this presentation, attendees will be able to:

 1. Summarize the new recommendations based on evidence and expert clinical remarks of the pharmacotherapy of stable COPD patients for the following outcomes:

  • alleviating symptoms, improving health status,
  • preventing exacerbations, and
  • reducing mortality

2. Apply a comprehensive management of COPD and a new “pharmacotherapy pathway” of stable COPD patients;

3. Integrate the new recommendations in clinical practice

CanMEDs Roles addressed : Medical Expert, Collaborator, Communicator, Health Advocate, Leader, Scholar